Insider Selling: InspireMD (NYSE:NSPR) Insider Sells 7,186 Shares of Stock

InspireMD, Inc. (NYSE:NSPR) insider Shane Thomas Gleason sold 7,186 shares of InspireMD stock in a transaction dated Friday, May 30th. The stock was sold at an average price of $2.51, for a total value of $18,036.86. Following the completion of the transaction, the insider owned 1,079,601 shares of the company’s stock, valued at $2,709,798.51. This trade represents a 0.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shane Thomas Gleason also recently made the following trade(s):

• On Tuesday, May 19th, Shane Thomas Gleason sold 22,778 shares of InspireMD stock. The stock was sold at an average price of $1.01, for a total value of $23,005.78.

InspireMD Price Performance

NYSE:NSPR traded up $0.03 during mid-day trading on Thursday, reaching $1.03. The stock had a trading volume of 160,140 shares, compared to its average volume of 182,457. The company has a market capitalization of $48.24 million, a price-to-earnings ratio of -1.37 and a beta of 0.82. InspireMD, Inc. has a 1-year low of $0.97 and a 1-year high of $2.93. The stock’s 50 day simple moving average is $1.40 and its two-hundred day simple moving average is $1.68.

Analysts Set New Price Targets

A number of equities analysts recently commented on NSPR shares. Piper Sandler reiterated an “overweight” rating and issued a $3.00 price target (down from $4.00) on shares of InspireMD in a research note on Tuesday, May 5th. Lake Street Capital set a $4.00 target price on InspireMD in a research note on Monday, May 4th. Loop Capital set a $5.00 target price on InspireMD in a research note on Tuesday, February 24th. Finally, Maxim Group assumed coverage on InspireMD in a research note on Monday, February 2nd. They issued a “buy” rating and a $6.00 target price for the company. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, InspireMD has an average rating of “Buy” and a consensus target price of $4.50.

InspireMD News Roundup

Here are the key news stories impacting InspireMD this week:

• Neutral Sentiment: Shane Thomas Gleason disclosed multiple recent sales of InspireMD shares, including transactions on May 19, May 23, May 27, May 29, May 30, and earlier January/February dates. Each filing says the sales were made to cover tax withholding obligations related to the vesting of equity awards, which makes the activity look more routine than a strategic exit. Article Title
• Neutral Sentiment: A new “Stock Forecast & Price Target” page for InspireMD may be contributing to increased trading interest, but the item itself does not include a specific rating change, earnings update, or business development that would clearly drive the shares. Article Title

Hedge Funds Weigh In On InspireMD

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Rosalind Advisors Inc. boosted its stake in InspireMD by 70.6% in the third quarter. Rosalind Advisors Inc. now owns 3,905,743 shares of the company’s stock valued at $9,413,000 after acquiring an additional 1,616,644 shares during the period. Nantahala Capital Management LLC boosted its stake in InspireMD by 45.7% in the third quarter. Nantahala Capital Management LLC now owns 3,376,484 shares of the company’s stock valued at $8,137,000 after acquiring an additional 1,058,467 shares during the period. Aberdeen Group plc boosted its stake in InspireMD by 27.9% in the fourth quarter. Aberdeen Group plc now owns 3,173,364 shares of the company’s stock valued at $5,649,000 after acquiring an additional 692,247 shares during the period. Orbimed Advisors LLC raised its holdings in shares of InspireMD by 46.9% during the fourth quarter. Orbimed Advisors LLC now owns 3,133,405 shares of the company’s stock valued at $5,577,000 after buying an additional 1,000,000 shares during the last quarter. Finally, Parkman Healthcare Partners LLC raised its holdings in shares of InspireMD by 97.6% during the third quarter. Parkman Healthcare Partners LLC now owns 2,440,633 shares of the company’s stock valued at $5,882,000 after buying an additional 1,205,328 shares during the last quarter. 44.78% of the stock is currently owned by institutional investors and hedge funds.

InspireMD Company Profile

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.